The market has knocked BioNTech’s shares about a quarter below their 52-week peak, but the German biotech is quietly assembling two major catalysts that could reshape its identity. A debut cancer drug filing in the United States is set for next year, and the company’s founders are carving out a new independent entity built on the mRNA platform that made BioNTech a household name during the pandemic.
The spin-off is on a tight timeline. Binding contracts for the transfer of certain mRNA rights and technologies must be signed by June 30. The new company, controlled by the founders, will take over the platform while BioNTech retains a minority stake along with future milestone payments and royalties. The restructuring also includes a consolidation of production sites, freeing up capital to pour into oncology research.
That oncology push now has a clear near-term goal. In 2026, BioNTech plans to submit its first ever US cancer drug application, for the antibody-drug conjugate Trastuzumab Pamirtecan in advanced endometrial cancer. The candidate, developed with partner DualityBio, has already secured FDA fast-track and breakthrough therapy designations. The filing is backed by a phase 2 cohort of 145 patients that delivered a confirmed objective response rate of 47.9% — climbing to 73.1% in those with the highest HER2 expression. Median progression-free survival stood at 8.1 months. Notably, the response rate held at 49.3% even in patients previously treated with checkpoint inhibitors, and activity was seen in lower HER2 expression levels where no approved HER2-targeted therapy currently exists. In China, the NMPA accepted the corresponding application for review in April.
Should investors sell immediately? Or is it worth buying BioNTech?
Trastuzumab Pamirtecan is only one piece of a much larger pipeline. BioNTech plans to launch six additional phase 3 studies during 2026, bringing its total number of late-stage trials to 15. Seven data packages from these programs are expected by year-end. Beyond endometrial cancer, the company is building evidence across multiple indications. The phase 2/3 ROSETTA Lung-02 study showed activity for Pumitamig plus chemotherapy in non-small cell lung cancer — the third global data signal for that asset after earlier results in small cell lung cancer and triple-negative breast cancer. Separately, Gotistobart combined with pembrolizumab produced durable responses and clinically relevant survival data in platinum-resistant ovarian cancer.
All this clinical work comes at a cost. First-quarter revenue fell to €118.1 million from €182.8 million a year earlier, driven by declining COVID-19 vaccine sales. The net loss widened to €531.9 million. Yet BioNTech’s balance sheet remains formidable: €16.8 billion in cash and securities at the end of March, providing ample runway for the pipeline. To support the share price during this transition, management launched a buyback program for American depositary receipts worth up to $1 billion, running through May 2027.
The full-year outlook is unchanged, with revenue expected between €2.0 billion and €2.3 billion and adjusted R&D spending of €2.2 billion to €2.5 billion. The company does not anticipate any oncology product revenue in 2026. The stock is testing chart support around €79.50 and has shed roughly 4% since the start of the year. Investors are waiting for clinical signals to translate into regulatory approvals — the next checkpoint comes on August 4 with second-quarter results.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 25 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 25.
BioNTech: Buy or sell? Read more here...
